Cantab Begins US Trial For LM-CD45
Cantab Pharmaceuticals and Baxter Healthcare have begun a multi-center, placebo-controlled Phase II trial in the USA for its lead product LM-CD45, in the prevention of rejection in kidney transplants.
LM-CD45, which is being co-developed with Baxter, is used to treat the donated kidney ex-vivo to remove passenger leukocytes from the organ before transplantation to try and prevent rejection.
The US trial will enroll 80 patients at up to 10 centers, including the Baylor University Medical Center in Dallas and Shands Hospital-University in Florida. Phase II trials are also currently ongoing in the UK. According to the company, if the trials are successful the product will enter Phase III shortly thereafter, and it would be expected to be approved for launch in 1997. Paul Haycock, chief executive, also noted that the product is being investigated for use in the control of rejection in other organ transplants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze